Crystalline Psilocybin Polymorphs for Scalable High-Purity Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing psilocybin are limited in scale, purity, and consistency, making it challenging to produce large batches suitable for clinical trials and commercial use, particularly for the treatment of treatment-resistant depression.
Innovation Solution
Development of crystalline psilocybin in specific polymorphic forms, such as Polymorph A and Polymorph A', characterized by distinct XRPD and DSC profiles, ensuring high chemical purity and stability, with methods to reproduce these forms consistently.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing psilocybin production methods are used, then production can be achieved at small scale, but batch size and productivity are limited
Solution Approach 1:
The patent applies parameter changes by optimizing reaction conditions including temperature ranges (0°C to reflux), solvent systems (dichloromethane, ethyl acetate, water), and stoichiometric ratios to enable scalable production while maintaining product quality and consistency across increasing batch sizes
Solution Approach 2:
The synthesis process is divided into discrete, manageable steps (acylation, amidation, reduction, crystallization) that can be independently optimized and controlled, facilitating systematic scale-up from gram to kilogram levels while maintaining manufacturing precision
2Manufacturing precision
If existing psilocybin production methods are used, then production can be achieved, but chemical purity and consistency are insufficient
Solution Approach 1:
The patent employs extraction and purification techniques including selective crystallization from ethyl acetate and water systems, which effectively remove impurities and achieve high chemical purity (>98%) while maintaining production efficiency through optimized solvent removal and crystal formation protocols
Solution Approach 2:
The patent replaces complex multi-step purification mechanisms with a streamlined crystallization-based purification system that achieves high purity through controlled solubility differences and crystal lattice formation, reducing manufacturing complexity while improving consistency
3Reliability
If existing psilocybin production methods are used, then production can be achieved, but batch-to-batch consistency is poor
Solution Approach 1:
The patent establishes controlled parameter ranges for temperature (0°C to reflux), pH, and solvent ratios that ensure reproducible reaction outcomes and crystal formation across batches, achieving high reliability through parameter standardization without requiring complex control systems
Solution Approach 2:
The patent achieves batch-to-batch consistency through homogeneous reaction conditions and uniform crystallization protocols, ensuring that all batches produce psilocybin with identical polymorphic form, purity, and physical properties through standardized operating procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves chemically pure, stable, and reproducible large-scale production of psilocybin, suitable for medical use, particularly in treating depression, with batch-to-batch consistency and suitability for digital health products.
Implementation Method 1
a reaction product separated by filtration and washed with n hexane, ethyl acetate, and water to obtain 3-Dimethylaminooxalyl-4-acetylindole (6)
Implementation Method 2
the organic phase dried over sodium sulphate and evaporated to obtain 4-acetylindole (4)
Implementation Method 3
Water was added, the mixture evaporated, and the resulting concentrate was dissolved in ethyl acetate
Data Source
AI summary
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.